Shareholders Reject Thermo Fisher's Executive Compensation Plan
TMO sits 16% above its 52-week low of $385.46.
Summary
Thermo Fisher Scientific shareholders voted against the advisory proposal on executive compensation at the annual meeting, while electing all nominated directors and ratifying the auditor.
Key Events · Corporate Governance and Compliance · TMO
-
Executive Compensation Proposal Rejected
The non-binding, advisory proposal on the compensation of named executive officers was not approved by shareholders, with 214,525,673 votes against compared to 99,928,178 for.
-
Board of Directors Elected
All eleven nominated directors, including Marc N. Casper and Nelson J. Chai, were elected to the Company's Board for a one-year term expiring at the 2027 annual meeting.
-
Auditor Ratified
The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified by shareholders.
Analysis · TMO · Industrial Applications And Services
Shareholders officially rejected the advisory proposal on executive compensation, confirming the low support indicated in prior proxy filings. This outcome signals significant shareholder dissatisfaction with the company's executive pay practices and will likely put pressure on the Board's compensation committee to review and potentially revise future compensation structures.
At the time of this filing, TMO was trading at $449.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $166.6B. The 52-week trading range was $385.46 to $643.99. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.